NEW YORK, Dec 7- Celera’s Wednesday evening announcement that it had submitted its human genome sequence data to Science has already provoked controversy in the scientific community and fueled speculation about how the Human Genome Project data will be published, leading Science to issue a statement Thursday to clarify the way it is handling Celera’s submission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.